Introduction: After any type of transplant is increased the risk of developing malignancy. This fact is mainly by the use of immunosuppressive agents that affect immunity against neoplastic cells and viruses which are major oncogenic factors. In addition, some immunosuppressive drugs are oncogenic by changing the DNA of cells and leading to proliferation. The risk of death from cancer is higher among transplant recipients, especially after several years after procedure. Methods/Results: We report the case of female, 38 years, underwent orthotopic liver transplantation in February 1998 due to liver cirrhosis for hepatitis C. After 9 years of the liver transplantation patient developed with constipation, abdominal pain and weight loss. Investigation showed expansive pelvic lesion measuring 12.5 × 9.0 × 8.3 cm in contact with the uterine wall. Exploratory laparotomy was held, and frozen biopsy of ovarian tumor demonstrated undifferentiated malignant neoplasm. The patient was submitted to bilateral salpingo-oophorectomy and hysterectomy, which showed a pathologic ovarian adenocarcinoma clear cell, stage IA. In the 3 ½ years follow-up, no evidence of recurrence was observed with tumor markers within normal limits. Conclusion: The development of malignancies after liver transplantation is a frequent complication and is a major cause of death in these patients. There is no literature describing cases of ovarian adenocarcinoma in liver transplanted patients. With respect to gynecological tumors is well described the increase of tumors of the cervix and vulva due to immunity against HPV 13 be. High serum levels of immunosuppressive drugs is not indicated in this cases. The use of mTOR inhibitors seem to be associated with a lower incidence of cancer, but studies are still lacking to prove this benefit. In our center.we have used sirolimus in cases of patients with hepatocellular carcinoma or when is present some type of cancer. Our patient is making use of sirolimus in a dose of 2 mg/day since the surgery with a serum level of 11.